From Gattaca To Digital Twins: The Future Of Biologic Data In Medicine

By Niven R. Narain, Forbes Councils Member.

Written for Forbes Technology Council

Published September 18, 2025, 07:30am EDT

In Gattaca, the 1997 sci-fi classic, a pair of siblings—one genetically engineered for perfection, the other naturally born—illustrate a dystopian vision where DNA determines destiny. The “in-valid” brother is denied opportunity not because of who he is, but because of what his genome might predict. At its core, the film is a cautionary tale of biological determinism—how genetic data, when misused, can restrict rather than empower.

Fortunately, real-world biology has followed a more promising trajectory. Since the Human Genome Project, the life sciences ecosystem—spanning government, academia and industry—has embraced biologic data to advance inclusion and precision. We’ve developed gene-editing technologies, created gene therapies and unlocked precision medicine, all fueled by an explosion of biologic insight.

But the future with biologic data doesn’t end here.

While much of the spotlight in AI over the past few years has focused on generative models and chatbot-like tools, the future lies in something far more biologically grounded: a dynamic, data-driven model of an individual’s biology, built using real patient samples, clinical records and multiomics data, that can simulate how real people respond to disease and treatment. In short, biological digital twins.

Full Story: From Gattaca To Digital Twins: The Future Of Biologic Data In Medicine

 

About BPGbio

          

BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.

Contact
Media Contact:
media@bpgbio.com